Synlogic Inc. said Tuesday that it has raised $29.4 million in a Series A financing led by Atlas Venture andNew Enterprise Associates.
The plan is to use the proceeds to develop a microbial engineering platform that can be used for making new drugs, the company said in a press release.
The company was incubated as part of the Atlas Venture seed program. Atlas is a venture capital firm based in Cambridge.
Synlogic was co-founded Dr. Ankit Mahadevia, Atlas Venture partner; Jim Collins, William Fairfield Warren Distinguished Professor, university professor, professor of biomedical engineering, and professor of medicine at Boston University; and Timothy Lu, associate professor of electrical engineering and biological engineering at the Massachusetts Institute of Technology.
“Synlogic leverages the most advanced technology platform available for the creation of synthetically engineered, therapeutic microbes with the potential to make significant advancements in the treatment of disease,” Mahadevia said in a statement.